Arecor strengthens management team to accelerate partnership opportunities
Cambridge, UK., 1 November 2019: Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces the appointment of Jim MacDonald-Clink as Vice President, Business Development with immediate effect.
Jim, who joins the Arecor Leadership team from Mundipharma, will be responsible for extending and expanding areas of growth. At Mundipharma, Jim was responsible for Business Development and established the biosimilar platform and oncology strategy via acquisition and licensing agreements. His experience includes acquisition, licensing and strategic partnering initiatives in specialist therapy areas as well as various roles in R&D, Medical and Commercial functions. Jim has over 25 years of experience in healthcare with Mundipharma, Astellas Pharma, Fujisawa, Institute of Cancer Research at the Royal Marsden and Institute of Child Health at Great Ormond Street Hospital, London, UK. Jim holds a degree in Medicinal Chemistry
Sarah Howell, Chief Executive Officer at Arecor, said: " We are delighted to welcome Jim to Arecor at a pivotal time in our evolution. He brings 25 years of experience and expertise in business development within the pharma industry, as well as in the broader areas of pharma development and commercialisation. Jim will play a key role in delivering our strategic business development plans as we strive to meet our ambitious goal of transforming patient care by bringing innovative medicines to market using our Arestat™ technology.”
For more information, please contact:
Arecor Limited is a biopharmaceutical company transforming patient care by bringing innovative medicines to market. Through the enhancement of existing medicines using our Arestat™ technology, we are developing a broad portfolio of therapies as part of our proprietary pipeline and through partnerships with leading pharmaceutical and biotech companies. Our treatments for people living with chronic disease are designed to simplify patient care and improve medication adherence.
Arestat™ is a world leading, innovative and proprietary formulation technology platform which significantly enhances the properties of approved therapeutic proteins and peptides. Arecor’s proprietary products leverage Arestat™ to enable improved treatments for diabetes including an ultra-rapid acting insulin for Type I diabetes and an ultra-concentrated (up to 100U/mL) rapid acting insulin, as well as a portfolio of undisclosed pre-clinical candidates. Our clinical programmes are significantly de-risked because we reformulate existing approved products with known safety and efficacy profiles.
For our partners, we use Arestat™ to deliver superior reformulations of their proprietary products, which would otherwise not be possible.
For further details please see our website, www.arecor.com